Our group leader Emma was interviewed and featured in Apollon, the award-winning science and research magazine published by the University of Oslo. The article, published in November 2022, focuses on our groundbreaking work in the field of gene editing for treating rare immune deficiency diseases.
Utilising the CRISPR-Cas9 technique, our research explores innovative treatments, including gene correction in stem cells and specialised immune cells. This advanced approach aims to address diseases where traditional treatments are less effective, holding promise for both immune deficiencies and certain cancers.
The article highlights the potential of CRISPR technology in revolutionising medical treatments and the challenges involved in its clinical application.
For a detailed read, check out the full article here (in Norwegian).